Parkinson's Disease — SCE Neurology MCQ

Instant feedback + full explanation. One question, done properly.

EasyMovement DisordersParkinson's DiseaseSCE Neurology

A 58-year-old man with Parkinson's disease has motor symptoms that significantly impact his quality of life. He has no cognitive impairment. Per NICE NG71, what should be offered as first-line pharmacotherapy?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: D — Levodopa

NICE NG71 states: offer levodopa to people in the early stages of Parkinson's disease whose motor symptoms impact on their quality of life. Levodopa provides the most improvement in motor symptoms and activities of daily living. B: Dopamine agonists are an option when symptoms do not impact QoL. C: MAO-B inhibitors are an option when symptoms do not impact QoL. D: Amantadine is used for dyskinesia management, not first-line. E: Apomorphine is for advanced PD with motor fluctuations.

Reference: NICE NG71 Parkinson's Disease (2017)